Premium
Heparin‐mediated neutralization of platelet antiaggregatory activity of prostacyclin (PGI 2 ): Studies on mechanism
Author(s) -
Saba Sabiha R.,
Saba Hussain I.
Publication year - 1985
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830200202
Subject(s) - prostacyclin , heparin , hemostasis , platelet , protamine , chemistry , pharmacology , thrombosis , platelet activation , biochemistry , medicine
Prostacyclin (PGI 2 ) is a well‐known potent inhibitor of platelet aggregation. Its role has been implicated in physiological and pathological states of hemostasis. Heparin blocks the prostacyclin‐mediated antiaggregatory activity on platelets. Prior treatment of heparin with heparinase as well as with protamine destroyed heparin's ability to neutralize PGI 2 . Studies on the mechanism of heparin blocking of PGI 2 activity suggested that heparin interacted directly with PGI 2 , as shown by the loss of PGI 2 mobility on thin layer chromatography concomitant with the loss of PGI 2 ‐mediated inhibition of platelet aggregation. PGI 2 in this combination with heparin, nevertheless, retained its time‐dependent ability to be hydrolyzed to 6‐keto‐PGF 1α . Findings of these studies may have implications in thrombosis and hemostasis, particularly in heparin‐mediated abnormalities of circulating platelets.